Targets › PNPLA3
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Aug 2027.
Specifically catalyzes coenzyme A (CoA)-dependent acylation of 1-acyl-sn-glycerol 3-phosphate (2-lysophosphatidic acid/LPA) to generate phosphatidic acid (PA), an important metabolic intermediate and precursor for both triglycerides and glycerophospholipids. Does not esterify other lysophospholipids. (UniProt, Q9NST1)
Open in Phaseline: the race on PNPLA3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals | ALN-PNP PNPLA3 inhibitor (reduces Patatin-like phospholipase domain-containing protein 3 expressio | PNPLA3 | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD); Healthy Volunteers | Aug 2027 |
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (1) Healthy Volunteers (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.